CA2511500A1 — Novel ethylenediamine derivatives
Assigned to Daiichi Pharmaceutical Co Ltd · Expires 2004-07-15 · 22y expired
What this patent protects
A compound represented by the following general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 (1) wherein R1 and R2 represent each hydrogen, etc.; Q1 represents optionally substituted and saturated or unsaturated 5- to 6-membered cyclic hydrocarbyl, etc.; Q2 represents a single bond…
USPTO Abstract
A compound represented by the following general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 (1) wherein R1 and R2 represent each hydrogen, etc.; Q1 represents optionally substituted and saturated or unsaturated 5- to 6-membered cyclic hydrocarbyl, etc.; Q2 represents a single bond, etc.; Q3 represents a group -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (wherein R3a to R4e represent each hydrogen, etc.); T0 represents carbonyl, etc.; and T1 represents -COCONR-, etc.; its salt, solvates thereof or N-oxides of the same. These compounds are useful as preventives and/or remedies for cerebral infarction, cerebral embolism, myocardial infarction, angina, pulmonary infarction, pulmonary embolism, Burger~s disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombosis after artificial valve/joint replacement, thrombosis and reocclusion after reconstructing blood circulation, systemic inflammatory response syndrome (SIRS), multiorgan dysfunction syndrome (MODS), thrombosis in extracorporeal circulation and blood coagulation in blood collection.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.